Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 20, 2022

Thrombosis Incidence in Relapsed/Refractory BCL Treated With Axicabtagene Ciloleucel

Leukemia and Lymphoma


Additional Info

Leukemia and Lymphoma
Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience
Leukemia and Lymphoma 2022 Feb 03;[EPub Ahead of Print], M Melody, S Gandhi, H Saunders, Z Abdel-Rahman, J Hastings, P Lengerke Diaz, N Gannon, T Truong, M Hathcock, A Khurana, P Johnston, S Ansell, N Bennani, J Paludo, JV Bisneto, Y Wang, A Rosenthal, J Foran, E Ayala, HS Murthy, V Roy, JE Castro, Y Lin, MA Kharfan-Dabaja

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading